BofA/Merrill Lynch analyst Jason Gerberry lowered the price target on Nabriva Therapeutics AG (NASDAQ: NBRV) to $5.00 (from ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE